糖解维护AMPK激活在sorafenib诱导的华堡效应中
Sijia Guo1, Chenhao Zhang1, Haiou Zeng2
1Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
肝细胞癌 (HCC) 的治疗耐药性与AMPK激活动态有关. 糖溶解的持续时间控制了这种激活,为这种致命的癌症提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症抵抗机制 癌症抵抗机制
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因,治疗选择有限.
- 索拉菲尼布是一种一线HCC治疗,通过有氧糖解 (Warburg效应) 诱导耐药性.
- AMP激活蛋白激酶 (AMPK) 调节新陈代谢,对索拉芬尼布耐药性至关重要,但其激活动态尚不清楚.
研究的目的:
- 在索拉芬尼布治疗期间调查HCC中AMPK的激活动态和调节.
- 阐明葡萄糖代谢在调节AMPK激活时间中的作用及其对治疗耐药性的影响.
主要方法:
- 开发和使用AMPK活动生物传感器,用于高通量单细胞监测.
- 在不同葡萄糖度的sorafenib治疗下,观察HCC细胞中的AMPK激活.
- 操纵糖解水平以评估它们对AMPK激活持续时间的影响.
主要成果:
- 索拉芬尼诱导HCC细胞中AMPK的暂时激活.
- AMPK激活的持续时间在很大程度上取决于葡萄糖的可用性和糖解.
- 抑制糖解缩短了AMPK的激活,而增加糖解则延长了它.
结论:
- AMPK激活的持续时间,而不仅仅是它的存在,对于癌细胞来说至关重要,以逃避像索拉芬尼布这样的治疗治疗.
- 糖解在确定HCC中AMPK激活的持续时间方面发挥着关键的调节作用.
- 向糖解可能是通过调节AMPK激活动态来克服HCC中索拉芬尼抗性的可行策略.
更多相关视频
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
10:26Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
Published on: October 21, 2022
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
PI3K/mTOR/AKT Signaling Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Glycolysis
cAMP-dependent Protein Kinase Pathways
